In continuation of my update on Paclitaxel and drug discovery....
Geron Corporation, announced the initiation of GRABM-B (GRN1005 Against Brain Metastases - Breast
Cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with
brain metastases arising from breast cancer. GRN1005 is the company's
lead LRP-directed peptide-drug conjugate (LRP-directed PDC) that
consists of the cytotoxic drug, paclitaxel, linked to a peptide
(Angiopep-2) that targets the LRP receptor to cross the blood-brain
barrier (BBB) and to target tumors in the brain.
The purpose of the Phase
2 study is to assess the efficacy, safety and tolerability of GRN1005
in patients with brain metastases from breast cancer. The trial is
designed to include 100 patients with HER2 positive or HER2 negative
metastatic breast cancer (MBC) disease, who will be assessed in two
separate cohorts of 50 patients each.....
Ref : http://www.geron.com/media/pressview.aspx?id=1287
